### CAMP

Quality by Design: A Challenge to the Pharma Industry

**CAMP Member Companies March 2002** 

# The Changing Healthcare Scene & Impact on the Pharmaceutical Industry

Ageing population



urgent need for new medicines & greater use of pharmaceuticals

BUT

Increasing healthcare costs



pressure to <u>reduce</u> use (and price) of pharmaceuticals

More informed payers & consumers




greater need to demonstrate health and economic value

#### Pressure comes in many forms...


- External pressures
  - diseases
  - shareholders
  - special interest groups
  - governmental agencies
- Internal pressures
  - > pipeline
  - speed to market
  - cost of goods
  - consolidation & merger savings
  - continuity of supply

# These pressures have driven innovation ...





### The typical pharmaceutical business model



## **V** Blenders





### Slant Cone Blenders






### Granulators





### Are manufacturing costs significant?


Cost Distribution: Big Pharma (16 Companies)



- Total sales > \$ 300 Bn
  - Total costs ~ \$ 250 Bn
- COS > \$ 90 Bn

# Where are the Quality and Financial Opportunities?

# Manufacturing Costs: Big Pharma



- \$45 Bn in materials
- \$22.5 Bn in personnel costs
- \$22.5 Bn in dep and operating
- Material
- Employment
- Maint & Util
- Depreciation

# The result of today's manufacturing processes:

- Large inefficient batch equipment
- Low utilization 30 40 % on average
- Capital and labor intensive
- High inventories and excessive warehouse space
- Elaborate HVAC and mechanical segregation
- High transportation costs
- High operating costs
- Low product yields
- Excessive amounts of product non-conformances
- Long lead-times due to stage and final product testing

### **Main points from this:**

- High tech in R & D
- Relatively low tech in Manufacturing
- It matters
  - Big Pharma manufacturing costs are \$ 90 Bn
  - Significantly more than R&D

#### How can we make a difference?

- Technology exists
  - Near infra-red
  - Laser induced fluorescence
  - Continuous processing
- On line monitoring and control to improve quality
  - Minimize troubleshooting and investigation systems
  - Prevent rather than repair
- Financial drivers are strong
  - 1% yield improvement = \$400 million in savings
- There are significant barriers
  - Cultural
  - Organizational
  - Historical


#### **Opportunities**

- Closer links between R&D and Mfg.
- Develop and design manufacturing scale processes ... before registration
- On line measurement and control
- Continuous processing
- Product plants ... not component plants
- Small dedicated facilities

# The future vision pharmaceutical business model

R&D Manufacturing Marketing

#### Process for new products



Roll out to sites with turnkey package

### Today: A challenge

Need a paradigm shift

Barriers are challenging

 Environment is ready to improve quality, shorten time to market and reduce costs

Will we take the step???